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GPR139 is an orphan G protein-coupled receptor that is expressed primarily in the brain. Not much is
known regarding the function of GPR139. Recently we have shown that GPR139 is activated by the amino
acids L-tryptophan and L-phenylalanine (EC50 values of 220 mM and 320 mM, respectively), as well as di-
peptides comprised of aromatic amino acids. This led us to hypothesize that GPR139 may be activated by
peptides. Sequence alignment of the binding cavities of all class A GPCRs, revealed that the binding
pocket of the melanocortin 4 receptor is similar to that of GPR139. Based on the chemogenomics prin-
ciple “similar targets bind similar ligands”, we tested three known endogenous melanocortin 4 receptor
agonists; adrenocorticotropic hormone (ACTH) and a- and b-melanocyte stimulating hormone (a-MSH
and b-MSH) on CHO-k1 cells stably expressing the human GPR139 in a Fluo-4 Ca2þ-assay. All three
peptides, as well as their conserved core motif HFRW, were found to activate GPR139 in the low
micromolar range. Moreover, we found that peptides consisting of nine or ten N-terminal residues of
a-MSH activate GPR139 in the submicromolar range. a-MSH1-9 was found to correspond to the product of
a predicted cleavage site in the pre-pro-protein pro-opiomelanocortin (POMC). Our results demonstrate
that GPR139 is a peptide receptor, activated by ACTH, a-MSH, b-MSH, the conserved core motif HFRW as
well as a potential endogenous peptide a-MSH1-9. Further studies are needed to determine the functional
relevance of GPR139 mediated signaling by these peptides.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
G protein-coupled receptors (GPCRs) constitute the largest
family of cell surface receptors, encoded by more than 800 genes in
humans (Fredriksson et al., 2003). Given the importance of GPCRs
in many aspects of physiology, they are among the most pursued.
. Gloriam), hbo@sund.ku.dk
thors).
Ltd. This is an open access article utargets for drug development and they account for approximately
19% of the established drug-targeted portion of the genome (Rask-
Andersen et al., 2011). However there is still a huge untapped po-
tential for drug discovery within the GPCR ﬁeld owing to the fact
that these drugs only act on less than a quarter of the 400 non-
olfactory GPCRs. Furthermore, 121 non-olfactory GPCRs are still
classiﬁed as orphan GPCRs, meaning that their endogenous ligands,
signaling pathways and biological functions have not yet been
identiﬁed (Southan et al., 2016).
The class A GPCR GPR139 is an orphan receptor meaning that its
endogenous agonist is unknown. The expression pattern of GPR139
has primarily been studied on the mRNA level and showednder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Abbreviations
Ac N-terminal acetylation
ACTH adrenocorticotropic hormone
CHO-GPR139 CHO-k1 cell line stably expressing the
human GPR139 receptor
CHO-M1 CHO-k1 cell line stably expressing the human
muscarinic acetylcholine receptor M1
cmp1a compound 1a (2-(3,5-dimethoxybenzoyl)-N-
(naphthalen-1-yl)hydrazine-1-carboxamide) a
GPR139 agonist
EC50 the concentration giving 50% of maximum response
GPCR G protein-coupled receptor
GPR139 G protein-coupled receptor 139
HPLC high performance liquid chromatography
LC-MS liquid chromatography-mass spectrometry
MALDI-TOF MS matrix-assisted laser ionization-time-of-ﬂight
mass spectrometry
MC3R the melanocortin 3 receptor
MC4R the melanocortin 4 receptor
MCH melanin-concentrating hormone
NH2 C-terminal amidation
NPC% net peptide content
PC1 prohormone convertase 1 enzyme
PC2 prohormone convertase 2 enzyme
Phe phenylalanine
POMC pro-opiomelanocortin
S% similarity %
TRH thyrotropin releasing hormone
Trp tryptophan
a-MSH a-melanocyte stimulating hormone
a-MSH1-10 peptide with the sequence SYSMEHFRWG
a-MSH1-9 peptide with the sequence SYSMEHFRW
a-MSH4-10 peptide with the sequence MEHFRWG
a-MSH4-13 peptide with the sequence MEHFRWGKPV
b-MSH b-melanocyte stimulating hormone
b-MSH5-22 peptide with the sequence
DEGPYRMEHFRWGFPPKD
g1-MSH g1-melanocyte stimulating hormone
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Matsuo et al., 2005; Süsens et al., 2006; Wagner et al., 2016). At-
tempts to perform autoradiography on brain slices from mice with
radioligands for GPR139 have failed (Kuhne et al., 2016; Liu et al.,
2015). While several antibodies against GPR139 are commercially
available, only one antibody against the N-terminal of GPR139 have
been described in the literature, which locate GPR139 expression to
the medial habenula and lateral septal nucleus (Liu et al., 2015).
Furthermore, GPR139 mRNA has been detected in high levels in the
hypothalamus, in the pituitary and in the habenula of the brain (Liu
et al., 2015; Matsuo et al., 2005;Wagner et al., 2016). These ﬁndings
have led to the hypothesis that GPR139 could be involved in the
regulation of food consumption and/or energy expenditure
(Wagner et al., 2016). Moreover, another study has shown that
activation of GPR139 with a surrogate agonist (JNJ-63533054) leads
to decreased spontaneous locomotion activity in rats (Liu et al.,
2015).
We have previously shown that both D- and L-isomers of the
aromatic amino acids tryptophan (Trp) and phenylalanine (Phe)
activate GPR139 via Gaq-coupling (Isberg et al., 2014). Recently, this
ﬁnding was conﬁrmed by Liu et al., that reported plasma levels of L-
Trp and L-Phe in rats in the dynamic range of GPR139 activity
(30e300 mM) (Liu et al., 2015). However, the potencies of L-Trp and
L-Phe on GPR139 are modest (EC50 values of 220 mM and 320 mM,
respectively), and interestingly, GPR139 is also activated by di-
peptides comprised of aromatic amino acids (Isberg et al., 2014).
This contrasts with other amino acids receptors, such as GPRC6A,
which require an intact a-amino acid moiety for agonist activity
(Christiansen et al., 2006). This has led us to hypothesize that
GPR139 is not simply an aromatic amino acid sensing receptor, but
could also be activated by peptides.
In the present study, we have searched for peptides that could
activate GPR139. Based on the chemogenomics principle that
“similar targets bind similar ligands”, we aligned the binding cavity
residues of GPR139 and all other class A GPCRs to identify known
peptide-binding GPCRs with similar binding cavities. In this
manner the melanocortin 4 receptor (MC4R) was identiﬁed as a
peptide-binding GPCR with a similar binding cavity to that
observed for GPR139. Peptide ligands acting on MC4R were tested
for activity on GPR139 in a Fluo-4 calcium assay. It was found thatthe adrenocorticotropic hormone (ACTH), a-melanocyte stimu-
lating hormone (a-MSH) and b-melanocyte stimulating hormone
(b-MSH) all activate GPR139.
2. Methodology and experimental procedures
2.1. Chemogenomic inference of peptide receptor ligands
The GPCRdb similarity search tool was used to identify class A
GPCRs with a similar binding pocket using the structure-based
GPCRdb numbering scheme (Isberg et al., 2015). A ﬁrst search
focused on a set of 15 generic peptide receptor-ligand interacting
residue positions annotated from all eight crystallized peptide
GPCRs available at the time (Isberg et al., 2016). A second search
involved all class A GPCR 44 accessible binding pocket residues
(Gloriam et al., 2009). The endogenous ligands of the ten most
similar peptide receptors were selected for testing on GPR139. We
also included the suggested ligand; b-alanine, for the orphan MAS-
related receptor (MRGRD_HUMAN) (Shinohara et al., 2004).
2.2. Commercially available endogenous peptides and amino acids
Ten peptide receptor ligands were purchased and tested. These
were: Adrenocorticotropic hormone (1e39) (human) (Tocris, Ox-
ford, UK, #3492, batch#3A) (ACTH); a-melanocyte stimulating
hormone (Tocris, #2584, batch#3A and Bachem, H-1075,
lot#1055067) (a-MSH); b-melanocyte stimulating hormone
(Sigma-Aldrich, Brøndby, Denmark #M-6513, lot#095K14351) (b-
MSH); and Melanotan II (Tocris, #2566, batch#4C and Bachem, H-
3902, lot#1056060), all of which are melanocortin 4 receptor
(MC4R) peptide agonists; g1-melanocyte stimulating hormone
(Tocris, #3424, batch#1A) (g1-MSH), which share a common motif
with ACTH, a-MSH and b-MSH; thyrotropin releasing hormone
(Sigma-Aldrich, #P1319, lot#BCBM8636V) (TRH), a thyrotropin
releasing hormone receptor peptide agonist; [Arg8]-vasopressin
(Tocris, #2935, batch#5A/162260), an arginine vasopressin recep-
tor 1a and 1b peptide agonist; oxytocin (Tocris, #1910, batch#14A),
a weak peptide agonist on the vasopressin receptor 1a; 26RFa
(Tocris, #4402, batch#1A), a pyroglutamylated RFamide receptor
peptide agonist; melanin-concentrating hormone (Tocris, #3806,
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peptide agonist; and the non-peptide b-alanine (Sigma-Aldrich,
#146064), the suggested ligand for the orphan MAS-related
receptor.
2.3. Quality control of commercially acquired ACTH, a-MSH, b-MSH
and g1-MSH
Analytic HPLC was carried out on a Dionex Ultimate 3000
system using an analytical Gemini-NX 3 mm C18 column
(4.6  250 mm). Flow rate 1 mL/min and UV detection at 200, 210,
225, 254 and 280 nm. Gradient: 0e30 min 0e100% B in A,
30e35 min 100% B, 30e35 min 100% Solvent A. Solvent A: 0.1% TFA
in H2O (v/v), Solvent B: 0.1% TFA, 10% H2O in MeCN (v/v/v). Data
analysis was carried out with Chromeleon Version 6.80 SP4 Soft-
ware. LC-MSwas carried out on an Agilent 1200 series system using
an Xbridge 3.5 mmC18 column (4.6 100mm). Flow rate 1 mL/min
and UV detection at 215, 254 and 280 nm and mass detection m/z
100e3000. Gradient: 0e30 min: 5e95% B in A. Solvent A: 0.1%
formic acid, 5% MeCN in H2O (v/v/v), Solvent B: 0.1% formic acid, 5%
H2O in MeCN (v/v/v). Data analysis was carried out with Bruker
Daltonics DataAnalysis Version 3.3 software. MALDI-TOF MS was
carried out on a BrukerMicroﬂex system.Matrix: ACCA (a-cyano-4-
hydroxy-cinnamic acid, Sigma-Aldrich #C8982) in MeCN/H2O/TFA
(500:475:25, v/v/v). Data analysis was carried out with Bruker
FlexAnalysis software version 3.4 (build 57).
2.4. Searching for novel endogenous peptides with similarity to
ACTH, a-MSH and b-MSH
The GPR139 active peptides (ACTH, a-MSH and b-MSH) were
used as queries to screen the entire SWISS-PROT database using
TBLASTN, and BLASTP (Altschul et al., 1990; Bateman et al., 2015;
Camacho et al., 2009). The aim was to potentially identify similar
peptides with unknown function and/or unknown target that could
activate GPR139.
2.5. Searching for alternative cleavage sites in the pre-pro-protein
POMC
Peptide sequence information for all class A peptide GPCR li-
gands was retrieved from the IUPHAR/BPS Guide to PHARMA-
COLOGY (Southan et al., 2016) and their location on their respective
precursors (pre-pro-proteins) were mapped. The dataset was
analyzed for ﬂanking amino acids on the N- as well as C-terminal
peptide ends. The identiﬁed cleavagemotif was then applied on the
pre-pro-protein POMC to search for alternative cleavage sites that
could reveal possible unknown peptides as well as shorter versions
of already known peptides.
2.6. Synthesized peptides
a-MSH4-13 (MEHFRWGKPV), a-MSH1-10 (SYSMEHFRWG), a-
MSH1-9 (SYSMEHFRW), a-MSH4-10 (MEHFRWG), conserved motif
(HFRW), and b-MSH5-22 (DEGPYRMEHFRWGFPPKD) were synthe-
sized by GenScript, NJ, USA with and without capping; N-terminal
acetylation (Ac) and C-terminal amidation (NH2), indicated with
the tag “cap-“. Additionally, a-MSHP-Ser (SY[pSer]SMEHFRWGKPV-
NH2) and ACTH1-16,P-Ser (SY[pSer]SMEHFRWGKPVGKK) were syn-
thesized by GenScript, NJ, USA. GenScript assessed the purity of the
custom-synthesized peptides by HPLC and MS. Furthermore;
GenScript performed a solubility test for all peptides and deter-
mined the net peptide content (NPC%) using a Vario MICRO Organic
Elemental Analyzer.2.7. Fluo-4 Ca2þ-assay
All peptides/ligands were tested for agonistic and antagonistic
effect on a CHO-k1 cell line stably expressing the human GPR139
(CHO-GPR139) kindly provided by H. Lundbeck A/S, Valby,
Denmark, and also on a CHO-k1 cell line stably expressing the
human muscarinic acetylcholine receptor M1 (CHO-M1) (The cDNA
Resource Center, Bloomsburg University, PA, USA, #CEM100TN00)
to assess speciﬁcity. The peptides/ligands that did not show agonist
activity on GPR139 were also tested as antagonists against EC80
(800 nM) of compound 1a (cmp1a) (Shi et al., 2011) (see structure
in Fig. SI1), also kindly provided by H. Lundbeck A/S. The CHO-
GPR139 cell line was grown in Dulbecco's modiﬁed Eagle's medium
(DMEM) F12-Kaighn's (Gibco, 21127, distributed by Invitrogen,
Nærum, Denmark) supplemented with 10% dialyzed fetal bovine
serum (Gibco, 26400, United States origin), 1% GlutaMAX™-I
(100X) (Gibco, 35050), and 100 units/mL penicillin and 100 mg/mL
streptomycin (Gibco, 15140) and 1.0 mg/mL geneticin (Invitrogen,
1181103). CHO-M1 was grown in Ham's F12 (Gibco, 21765) sup-
plemented with 10% fetal bovine serum (Gibco, 10270, South
America origin) þ 100 units/mL penicillin and 100 mg/mL strepto-
mycin and 0.25 mg/mL geneticin. Cmp1a (H. Lundbeck, A/S) and
carbamoylcholine chloride (Sigma-Aldrich, C4382) was used as
positive controls in the two cell lines, respectively.
30,000 cells/well (either CHO-GPR139 or CHO-M1) were plated
in black 96-well plates with ﬂat clear bottoms (Corning, Falcon, ref
353219, distributed by VWR, Søborg, Denmark) and incubated
overnight. The Fluo-4 dye loading solution (Invitrogen, F36206)
was prepared according to the manufacturer's instructions by dis-
solving it in HEPES buffer (HBSS (Invitrogen, 14175129) supple-
mented with 10 mM HEPES, 1 mM MgCl2, 1 mM CaCl2, pH ¼ 7.4)
supplemented with 2.5 mM probenecid (HEPES-probenecid
buffer). 50 mL dye loading solution was added to each well. Cells
were incubated with the Fluo-4 dye for 60 min at 37 C, then
washed with 100 mL HEPES buffer.
Agonist testing. 100 mL HEPES-probenecid buffer was then
added to each well and incubated for 10 min at 37 C before
measurement. All peptides/ligands were diluted according to the
manufacturer's or GenScript's recommendation and in low-binding
micronic tubes (Micronic, MP32022, distributed by In Vitro A/S,
Fredensborg, Denmark). For testing agonist activity, the peptides
were transferred to low-binding ligand plates (Greiner bio-one, PS-
microplate, non-binding, U-bottom, 650901, distributed by In Vitro
A/S) before 33 mL of the test peptides (4  concentrated) were
added automatically after baseline measurements.
Antagonist testing. 100 mL of the peptides/ligands dissolved in
HEPES-probenecid buffer (in micronic tubes as described above)
was added to each well and incubated for 10 min at 37 C before
measurement. The antagonist activity was tested against EC80 of
cmp1a (800 nM) added automatically as 33 mL (4 ) after baseline
measurements.
Changes in intracellular calcium levels was recorded on a Flex-
Station 3 (Molecular Devices, serial no. FV05958) at 37 C with an
excitation ﬁlter of 485 nm and an emission ﬁlter of 520 nm.
2.8. cAMP accumulation assay
a-MSH-derived peptides (a-MSH, a-MSH1-9, cap-a-MSH1-9 and
Melanotan II)were functionally characterized invitro in termsof their
activity on Gas-coupled melanocortin receptors, MC3R and MC4R
transiently expressed in COS7 cells using cAMP accumulation assay
(HitHunter® cAMP assay, DiscoverX, Fremont, CA, USA, 90-0075SM).
TheCOS-7cell linewasgrown inDulbecco'smodiﬁedEagle'smedium
(DMEM) with 1000 mg/l glucose (Sigma-Aldrich, D6046) supple-
mented with 10% fetal bovine serum (Gibco, 10270, South America
A.C. Nøhr et al. / Neurochemistry International 102 (2017) 105e113108origin, lot#42G4850K), 1% GlutaMAX™ (100X) (Gibco, 35050), and
100 units/mL penicillin and 100 mg/mL streptomycin (Sigma-Aldrich,
P0781). 20,000 cells/well were plated inwhite opaque 96-well plates
(Perkin Elmer, CulturPlate-96, 6005680) and transfected the dayafter
seeding using Lipofectamine 2000™ reagent (Invitrogen, 11668) in
serum-free Opti-MEM I medium (Gibco, 31985) with 30 ng DNA of
respective receptor or mock plasmid construct in pcDNA3.1(þ) ac-
cording to the manufacturer's protocol.
Assays were performed one day after transfection. Cells were
washed with PBS and incubated in 30 mL PBS supplemented with
1mM3-isobutyl-1-methylxanthine (IBMX,CaymanChemical,13347)
for 30minprior to stimulationwithagonist. All peptides/ligandswere
diluted according to the manufacturer's or GenScript's recommen-
dation and dilutions were prepared in low-binding micronic tubes
(Micronic, MP32022). Serial dilutions of agonist were added to PBS
with IBMX (1.5 mL, 20 dilution) and cellswere stimulated for further
30min at 37 C. Intracellular cAMP detectionwas carried out directly
after the ligand stimulation. 10 mL anti-cAMP antibody followed by
40 mL chemiluminescent substrate/lysis buffer/enzyme donor-cAMP
complex mix prepared according to manufacturer's protocol were
added and plates were incubated shaking for 1 h at ambient tem-
perature. Finally, 40 mL enzyme acceptor was dispensed and chemi-
luminescent signal was quantiﬁed after 4e5 h in TopCount
Microplate Scintillation Counter (Packard, serial no. 409252) for 5 s/
well with 1 min counting delay before each plate.
2.9. Data analysis
The peptide concentration was calculated using the net peptide
content (NPC%) and peptide purity. All pharmacological data were
analyzed using GraphPad Prism (version 6.0h for Mac OS X
Yosemite, GraphPad Software, La Jolla California, USA, www.Fig. 1. GPR139 and peptide receptors have similar transmembrane ligand binding cavities. To
proposed binding cavity are highlighted in red. Bottom: Alignment of the residues located in
GPCRs. Circles in front of receptor name; Green: peptide, and Grey: orphan. Grey/Orange: G
IUPHAR (Prossnitz and Filardo, 2016). Abbreviations: I% ¼ percent sequence identity, S% ¼
(Isberg et al., 2016). Residue numbering is according to GPCRdb numbering system (Isberg et
is referred to the web version of this article.)graphpad.com). Data presented is from at least three independent
experiments in triplicates. The responses in Fig. 2 were normalized
to the responses of buffer (0%) and Emax (8 mM) of cmp1a (100%).
The responses in Fig. 4A is normalized to the responses of buffer
(0%) and Emax of a-MSH (100%). Fig. 4B were normalized to the
background signalling measured for mock-transfected cells (0%)
and Emax of a-MSH (100%). All graphs in Fig. 2 and 4 are shown as
mean ± SEM. Fitting of concentration-response curves was per-
formed by non-linear regression.
R ¼ Rmin þ
ðRmax  RminÞ
1þ 10ðlog EC50XÞ,nH
where X is the logarithm of the concentration, R is the response,
EC50 is the concentration giving 50% of maximum response and nH
is the Hill coefﬁcient, which describes the slope. In Fig. 2 for con-
centration response curves that reached a plateau (ACTH, a-MSH,
b-MSH, a-MSH1-9, a-MSH1-10 and HWFR) Rmin was ﬁxed to 0 and
Rmax was ﬁxed to the response of the maximum concentration
tested. For the concentration response curves that did not reach a
plateau (cap-a-MSH1-9, cap-a-MSH1-10, cap-HWFR, a-MSH4-10 and
cap-a-MSH4-10) the relative Emax ± SEM compared to Emax of cmp1a
is given for the highest peptide concentration tested. In Fig. 4A, a-
MSH and a-MSH1-9 was ﬁtted where Rmin was ﬁxed to 0 and Rmax
was ﬁxed to the response of the maximum concentration tested. In
Fig. 4B only melanotan II and a-MSH were ﬁtted.3. Results
3.1. Inferred endogenous peptide ligands
The binding cavity of GPR139 aligned to class A receptorsp: A 2D snake-like diagram sequence representation of GPR139. Residues located in the
the proposed binding cavity of GPR139 to the corresponding residues in all other class A
PER a target with a proposed ligand in several publications but not yet conﬁrmed by
percent sequence similarity, S ¼ similarity score. The alignment was made in GPCRdb
al., 2015). (For interpretation of the references to colour in this ﬁgure legend, the reader
Fig. 2. Concentration response curves of the active peptides on GPR139. GPR139 ac-
tivates the Gq signaling pathway leading to an increase in intracellular Ca2þ in CHO-
cells stably expressing the human GPR139, which was measured in a Fluo-4 Ca2þ-
assay. Compound 1a (cmp1a) is a surrogate GPR139 agonist used as a control. The Ca2þ
response induced by buffer and by 8 mM cmp1a (Emax of cmp1a) are represented by
dotted lines. Data are mean ± SEM of three experiments performed in triplicates and
normalized to buffer and Emax of cmp1a. A) Ca2þ response of the endogenously
expressed peptides; ATCH, a-MSH and b-MSH on GPR139, B) Ca2þ response of the two
conserved motifs; HFRW and a-MSH4-10 (capped and un-capped), C) Ca2þ response of
the two N-terminal ends of a-MSH; a-MSH1-9 and a-MSH1-10 (capped and un-capped).
A.C. Nøhr et al. / Neurochemistry International 102 (2017) 105e113 109revealed many orphan receptors similar to GPR139 (Fig. 1), among
which GPR142 was the most similar with 80% similarity. Six
peptide-binding GPCRs possess a similar ligand-binding pocket to
GPR139, including MC4R with a sequence similarity of 49%. On this
basis, we purchased and tested the ten known endogenous or
synthetic peptide ligands on the human GPR139, which are; ACTH,
a-MSH, b-MSH, g1-MSH, Melanotan II, TRH, [Arg8]-vasopressin,
oxytocin, 26RFa, and MCH. No agonist or antagonist activity on
GPR139 was detected for g1-MSH, Melanotan II, TRH, [Arg8]-
vasopressin, oxytocin, 26RFa, and MCH (data not shown). However,
ACTH, a-MSH, b-MSH all showed agonist activity on GPR139.
3.2. Activity of endogenously POMC-derived peptides
ACTH, a-MSH, b-MSH and g1-MSH all originate from the pre-
protein POMC. The concentration-response curves of ACTH, a-
MSH and b-MSH on CHO-GPR139 cells showed that ACTH
(EC50 ¼ 2.06 mM), a-MSH (EC50 ¼ 2.21 mM) and b-MSH
(EC50 ¼ 6.3 mM) all have lowmicromolar potencies on GPR139, and
are as efﬁcacious as the reference surrogate agonist cmp1a (Fig. 2A
and Table 1). ACTH, a-MSH and b-MSH had no detectable impu-
rities (incl. L-Phe and L-Trp), as determined by rigorous HPLC, LC-MS
and MALDI-TOF MS analysis (Fig. SI2). Furthermore, when we
tested for speciﬁcity, none of these peptides showed any activity on
the muscarinic acetylcholine M1 (M1) receptor (data not shown).
3.3. Activity of peptides with the HFRW motif
Next, we examined which part of the peptides were important
for GPR139 activation. The active peptides (ACTH, a-MSH and b-
MSH) share the amino acid sequence motif MEHFRWG (a-MSH4-10),
and all POMC-derived peptides (includes also g1-MSH) the sub-
motif HFRW (Table 1). When peptides representing both motifs
were tested on GPR139 only the HFRW peptide was found to be
active (EC50 ¼ 4 mM) (Fig. 2B). Since the longer sequence motif
MEHFRWG (a-MSH4-10) itself was inactive, we set out to determine
whether the C- or N-terminus of a-MSH is important for activating
GPR139. Therefore, a-MSH was truncated in both ends for the
amino acids ﬂanking the MEHFRWG motif. This gave two 10-mer
analogues of a-MSH with 3 residue truncations at the C- or N-ter-
minus; a-MSH1-10 and a-MSH4-13, respectively, which were tested
on GPR139 (Table 1). Interestingly, only the C-terminally truncated
analogue a-MSH1-10 was active (EC50 ¼ 318 nM) (Fig. 2C).
Subsequently, we looked for other peptides sharing the HFRW
motif. Our BLASTP and TBLASTN searches for novel uncharacterized
peptides with similarity to the queries did not result in any similar
or homologues peptides. However, our search for peptides con-
taining the conserved core motif HFRW, revealed 6 new proteins,
two of which (PKD1_HUMAN and RM27_HUMAN) are known and
predicted to be secreted, respectively. These proteins are well
characterized but are not known to play any role in GPR139
signaling; besides, nothing is known about their proteolytic pro-
cessing suggesting that the HFRWmotif originates exclusively from
POMC. We also looked for potential cleavage sites along the POMC
and one additional truncated analogue of a-MSH (a-MSH1-9) that
was active on GPR139 was identiﬁed (EC50 ¼ 596 nM) (Figs. 2C and
3).
Endogenously ACTH and b-MSH have free N- and C-termini,
unlike a-MSH that is acetylated at the N-terminus and amidated at
the C-terminus. In addition to the naturally occurring peptides,
capped and uncapped analogues were also custom-synthesized
and tested on GPR139 (Table 1). All capped peptides were less
potent than the non-capped versions. The exact reason for the
observed difference in potency remains unclear at this time and
future studies are needed to understand the underlying reasons forthe reduced activity.
In order to compare the selectivity and rank-order potency of a-
MSH, a-MSH1-9 and cap-a-MSH1-9 on GPR139 compared to the
MC4R, we tested the peptides in a cAMP assay on COS7 cells
transiently transfectedwithMC4R. a-MSH had a potency of 430 nM
on MC4R and a-MSH1-9 did not show any effect on MC4R (Fig. 4B).
Table 1
Potencies, efﬁcacies and peptide sequence alignment of the POMC derived peptides and analogues. The mean pEC50 ± SEM, mean EC50 and the relative Emax ± SEM (compared
to the surrogate GPR139 agonist cmp1a) of 3 experiments performed in triplicates and normalized to buffer (0%) and Emax of cmp1a (100%) are shown to the left. To the right is
shown a peptide sequence alignment of all POMC derived peptides and analogues. Abbreviations: Ac:N-terminal acetylation, NH2: C-terminal amidation, cap-: the peptides are
N-terminal acetylated and C-terminal amidated, SEM: standard error of mean, ND: not determined, NA: not active. ATCH, a-MSH, b-MSH, the conserved motif HFRW activate
Ca2þ-responses in CHO-cells expressing the GPR139 in the lowmicromolar range, and the N-terminal of a-MSH (both a-MSH1-10 and a-MSH1-9) activate Ca2þ-responses in the
submicromolar range.
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in the highest concentration, which is comparable to the response
on GPR139. Melanotan II was also tested onMC4R (EC50¼ 11 nM) as
control as it is a known synthetic agonist of the receptors, but
melanotan II had no effect on GPR139 (Fig. 4). As an additional
control experiment a-MSH, a-MSH1-9, cap-a-MSH1-9 and melano-
tan II were tested on the MC3R in the cAMP assay and peptides
showed the same rank-order potency of the agonists as on theFig. 3. A potential new cleavage site in the precursor POMC and physiological peptide.
The blue arrows and asterisks indicate a potential new cleavage site on the precursor
POMC represented by the motif GK right after the conserved motif HFRW on a-MSH1-9.
Red asterisks and arrows indicate known cleavage motifs on POMC leading to a-MSH.
The red box indicates a-MSH and the blue box indicates a-MSH1-9, which is a putative
new physiological peptide of POMC. (For interpretation of the references to colour in
this ﬁgure legend, the reader is referred to the web version of this article.)MC4R (Fig. SI3).
During the preparation of this manuscript the Dr. Jesper V. Olsen
group performed a large-scale mass spectrometry-based peptido-
mics of the rat hypothalamus and identiﬁed thousand of neuro-
peptides and their post-translational modiﬁcations including two
novel neuropeptides cleaved from POMC; a-MSHP-Ser and ACTH1-
16,P-Ser (Table 1), both of which are phosphorylated (Secher et al.,
2016). However, neither of the two peptides showed any agonist
or antagonist activity on GPR139 (data not shown).
All custom synthesized peptides were of >95% purity (UV
detection at 220 nm) with no signiﬁcant impurities observed when
analyzed by HPLC andMS at GenScript (Fig. SI4 and SI5) and the net
peptide content (NPC%) was determined for all custom synthesized
peptides at GenScript (Table SI1).4. Discussion
We found that the binding cavity of GPR139 mainly resembles
that of peptide receptors, including MC4R (Fig. 1). GPR139 has been
shown to signal trough Gas (Hu et al., 2009), Gai (Süsens et al.,
2006) and Gaq (Dvorak et al., 2015; Isberg et al., 2014; Liu et al.,
2015; Matsuo et al., 2005; Shehata et al., 2016; Shi et al., 2011;
Wang et al., 2015), however in CHO-k1 cells GPR139 only signals
via the Gaq-coupled signaling pathway (Isberg et al., 2014; Shehata
et al., 2016). The main signaling pathway of MC4R is through Gas
(reviewed in (Tao, 2010)). Accordingly, the Fluo-4 Ca2þ-assay and
the cAMP were used to measure the activity of GPR139 and MC4R,
respectively. Three physiological peptide ligands of MC4R, POMC-
derived peptides ACTH, a-MSH and b-MSH, were found to also
activate GPR139 with potencies in the single micromolar range
(Fig. 2 and Table 1). a-MSH had high nanomolar potency on MC4R
Fig. 4. a-MSH activates both GPR139 and MC4R, whereas a-MSH1-9 only activates
GPR139 and melanotan II only activates MC4R. Concentration-response curves of a-
MSH, a-MSH1-9, cap-a-MSH1-9 and melanotan II on A) GPR139 in a Fluo-4 Ca2þ-assay.
The Ca2þ response induced by buffer is represented by a dotted line. The Ca2þ re-
sponses are normalized to Emax of a-MSH, B) MC4R in a cAMP assay. The cAMP
response induced in mock transfected cells is represented by a dotted line. The cAMP
responses are normalized to Emax of a-MSH.
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did not show any activity on GPR139 (Table 1). Likewise, g1-MSH
did not have activity on the MC4R (Pritchard et al., 2004). We
have shown that the rank-order potency of peptides at GPR139 are
a-MSH1-9 > a-MSH > cap-a-MSH1-9 >> melanotan II and at MC4R
melanotan II > a-MSH > cap-a-MSH1-9 >> a-MSH1-9. Together this
data concludes that GPR139 and the MC4R have an overlapping but
also divergent agonist proﬁles.
MC4R is a class A GPCR highly involved in mammalian energy
homeostasis and body weight as Mc4r-/- knockout mice show overt
obesity (Huszar et al., 1997). Critically, heterozygous loss of function
mutations in MC4R represent the commonest genetic form of hu-
man obesity (Farooqi et al., 2003, 2000; Vaisse et al., 2000). Studies
in mice and humans have shown that, in addition to effects on
food intake and body weight, melanocortin signalling is involved in
the modulation of insulin secretion, linear growth and blood
pressure by modulating sympathetic tone (Ellacott and Cone,
2006). Our data suggest that GPR139 may potentially also be
important in mediating some of the effects attributed to melano-
cortin peptides.
Matsuo et al. and Liu et al. show that GPR139 mRNA is detected
in high levels in the hypothalamus and in the pituitary (Liu et al.,
2015; Matsuo et al., 2005) and Süsen et al. show that it isexpressed in the CA1 area of the hippocampus (Süsens et al., 2006).
Interestingly, POMC is expressed in the pituitary and in the hypo-
thalamus and ACTH, a-MSH and b-MSH are secreted in those areas
of the brain (Bergeron et al., 2000; Kato et al., 2004). ACTH and the
MSH-peptides originate from the pre-pro-protein POMC (Fenger
and Johnsen, 1988). POMC can be processed by the prohormone
convertase 1 enzyme (PC1) and the prohormone convertase 2
enzyme (PC2) leading to a range of peptide hormones (Benjannet
et al., 1991; Thomas et al., 1991). POMC and PC1 are expressed in
corticotroph cells of the anterior pituitary, and POMC is processed
by PC1 to ACTH in these cells (Kato et al., 2004). In the hypothal-
amus PC2 is additionally expressed (together with PC1 and POMC),
which can process ACTH further to give a-MSH and POMC to b-MSH
and g1-MSH (Bergeron et al., 2000). It is notable that GPR139 is
expressed in the same areas of the brain as POMC-derived
hormones.
The MC4R is also expressed in the CNS particularly in the hy-
pothalamus and in the CA1 and CA2 area of the hippocampus
(Gantz et al., 1993; Kishi et al., 2003; Mountjoy et al., 1994). It is
noteworthy that the GPR139 and MC4R receptors are expressed in
broadly similar areas of the brain and that they share some of the
same ligands, although with different potency and rank-order.
Interestingly, our data show that ACTH, a-MSH and b-MSH are a
100-fold less potent on GPR139 than on the MC4R. However, they
are 20e120 fold more potent on the GPR139 receptor than L-Trp
(EC50 ¼ 220 mM) and L-Phe (EC50 ¼ 320 mM) (Isberg et al., 2014)
(Fig. 2A and Table 1). Moreover, the conserved HFRW motif alone
(shared between ACTH, a-MSH, b-MSH and g1-MSH) is able to
activate GPR139 in the low micromolar range. This suggests that
GPR139 is a peptide-binding receptor, since ACTH, a-MSH and b-
MSH all are more potent on GPR139 than L-Trp and L-Phe.
Concentrations of a-MSH and b-MSH in human cerebrospinal
ﬂuid are in the high picomolar range (Berrettini et al., 1985; Shuster
et al., 1977), but can locally be present in higher concentration. a-
MSH and b-MSH have nanomolar potencies at the MC4R (Fig. 4B)
(Pritchard et al., 2004). Thus, it is reasonable to propose that a-MSH
and b-MSH most likely do not activate GPR139 in vivo, due to their
lower potency at GPR139. However, it is well known that agonist
potency at GPCRs is greatly affected by receptor expression levels
and cellular context (e.g. G protein levels) (Br€auner-Osborne et al.,
1996) and it is thus plausible that the peptides identiﬁed in the
present study could display higher GPR139 receptor potency
in vivo. It is also possible that alternative peptides with an HFRW-
like motif are the endogenous agonists or that another post-
translational modiﬁed POMC-derived peptide, than tested here,
displays higher GPR139 potency or physiological level and is the
'true' endogenous agonist.
Through computational analysis we found a new putative
cleavage site on the POMC leading to the peptide a-MSH1-9.
Although neither PC1 or PC2 can cleave at a single K residue, other
peptides such as neuropeptide SF/FF (NPFF), growth hormone-
release hormone (GHRH), corticotrophin-releasing hormone
(CRH), urocortin 1 (UCN1), neuromedin S-33 (NMS) and RFamide-
related peptide-1 (NPVF) are cleaved at a GK or GR motif. a-
MSH1-9 incorporates the HFRW motif and displays a GPR139 po-
tency in the submicromolar range, furthermore a-MSH1-9 does not
activate MC4R or MC3R. However, the peptide was not found in the
mass spectrometry proteomics compendium of peptideAtlas
(Farrah et al., 2011); in the mass spectrometry peptidomics of the
rat hypothalamus (Secher et al., 2016); or in the small open reading
frames predicted peptides of similar genes (sORfs.org) (Olexiouk
et al., 2015). Peptides that are secreted in low quantities are difﬁ-
cult to detect in proteomics experiments (Farrah et al., 2013) and
this could provide an explanation to its apparent absence in the
databases (vide supra).
A.C. Nøhr et al. / Neurochemistry International 102 (2017) 105e113112Overall, the results reported herein strongly suggest that
GPR139 is a peptide receptor and not simply a receptor for aromatic
amino acids. If a-MSH1-9 is present endogenously it could poten-
tially be the endogenous ligand for GPR139, especially because a-
MSH1-9 is selective to GPR139 when compared to similar receptors
(MC4R and MC3R). However, the a-MSH1-9 peptide has to be
identiﬁed physiologically in the brain in relevant concentrations to
substantiate this hypothesis.
5. Conclusions
This is the ﬁrst study to report that endogenously expressed
peptides can activate the orphan receptor GPR139. ACTH, a-MSH, b-
MSH, C-terminally truncated a-MSH (a-MSH1-9 and a-MSH1-10),
and the conserved core motif HFRW can all activate GPR139 in the
sub- to low micromolar range. These results indicate that the pre-
viously reported aromatic amino acids are not the most potent
endogenous agonists of GPR139. GPR139 is therefore more likely to
be a peptide receptor.
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